Studies men with prostate cancer on active surveillance to find markers
Looks for markers that tell aggressive prostate cancers apart from slow-growing ones.
Plain-language title generated from the registry record
Registry title: Prostate Active Surveillance Study
Key facts
- Where
- Vancouver, CanadaSee the site
Where in Canada
- University of British ColumbiaVancouver, CanadaTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- University of Washington
- Trial code
- NCT00756665
- Record updated
- 2 September 2026
- Original description
The Prostate Active Surveillance Study (PASS) is a research study for men who have chosen active surveillance as a management plan for their prostate cancer. Active surveillance is defined as close monitoring of prostate cancer with the offer of treatment if there are changes in test results. This study seeks to discover markers that will identify cancers that are more aggressive from those tumors that grow slowly.Read full original descriptionShow less
Canary Prostate Active Surveillance Study
The Prostate Active Surveillance Study (PASS) is a research study for men who have chosen active surveillance as a management plan for their prostate cancer. Active surveillance is defined as close monitoring of prostate cancer with the offer of treatment if there are changes in test results. This study seeks to discover markers that will identify cancers that are more aggressive from those tumors that grow slowly.
Inclusion: Histologically confirmed adenocarcinoma of the prostate from a prostate biopsy; Clinically localized prostate cancer: T1-2, NX or N0, MX or M0; No previous treatment for prostate cancer (including hormonal therapy, radiation therapy, surgery, or chemotherapy); ECOG Performance Status 0 or 1; Patient has elected Active Surveillance as preferred management plan for prostate cancer; Patient consent has been obtained according to local Institutional Review Board for acquisition of research specimens; Patient is accessible and compliant for follow-up; Prostate cancer diagnosis cannot be more than 3 years prior to baseline visit date; No more than two prostate biopsies including the initial biopsy in which cancer was diagnosed; If cancer diagnosis is more than one year before enrollment, there must be two prostate biopsies including the initial biopsy in which cancer was diagnosed and a subsequent biopsy. The subsequent biopsy may occur on the same day as the baseline visit; Biopsies must have at least 10 cores.
Exclusion: History of other malignancies, except: adequately treated non-melanoma skin cancer or adequately treated superficial bladder cancer (Ta) or other solid tumors curatively treated with no evidence of disease for > 5 years; Unwillingness or inability to undergo serial prostate biopsy.